Om

Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases. Its core work centers on T cell-based in vitro diagnostic technologies and immunology profiling tools designed to help assess immune risk related to viral and immune-mediated conditions. The company develops and commercializes diagnostic test kits and related med-tech products under the ViraxClear brand, while its ViraxImmune platform is intended to support immune profiling and the evaluation of post-viral syndromes such as Long COVID and other chronic immune dysfunction states. Virax Biolabs Group Ltd. serves healthcare and research-oriented markets where viral detection, immune assessment, and diagnostic support are important, positioning the company within the broader biotechnology and in vitro diagnostics sectors. The company is headquartered in BioCity Glasgow, United Kingdom.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VIRAX BIOLABS GROUP MED ENDAVU: Køb Virax Biolabs Group ($VRAX) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Virax Biolabs Group, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.